scholarly journals Identification of Risk Factors and Cross-Reactivity of Local Anesthetics Hypersensitivity: Analysis of 14-Years’ Experience

2021 ◽  
Vol Volume 14 ◽  
pp. 47-58
Author(s):  
Ilkay Koca Kalkan ◽  
Gozde Koycu Buhari ◽  
Hale Ates ◽  
Buket Basa Akdogan ◽  
Ozlem Erdem Ozdedeoglu ◽  
...  
Keyword(s):  
Risk Factors ◽  
Local Anesthetics ◽  
Cross Reactivity

scholarly journals Cephalosporins: A Focus on Side Chains and β-Lactam Cross-Reactivity

Pharmacy ◽  
2019 ◽  
Vol 7 (3) ◽  
pp. 103 ◽  
Author(s):  
Saira B. Chaudhry ◽  
Michael P. Veve ◽  
Jamie L. Wagner
Keyword(s):  
Risk Factors ◽  
Clinical Practice ◽  
Antimicrobial Stewardship ◽  
Clinical Utility ◽  
Cross Reactivity ◽  
Penicillin Allergy ◽  
Side Chain ◽  
Safety And Efficacy ◽  
History Of

Cephalosporins are among the most commonly prescribed antibiotic classes due to their wide clinical utility and general tolerability, with approximately 1–3% of the population reporting a cephalosporin allergy. However, clinicians may avoid the use of cephalosporins in patients with reported penicillin allergies despite the low potential for cross-reactivity. The misdiagnosis of β-lactam allergies and misunderstanding of cross-reactivity among β-lactams, including within the cephalosporin class, often leads to use of broader spectrum antibiotics with poor safety and efficacy profiles and represents a serious obstacle for antimicrobial stewardship. Risk factors for cephalosporin allergies are broad and include female sex, advanced age, and a history of another antibiotic or penicillin allergy; however, cephalosporins are readily tolerated even among individuals with true immediate-type allergies to penicillins. Cephalosporin cross-reactivity potential is related to the structural R1 side chain, and clinicians should be cognizant of R1 side chain similarities when prescribing alternate β-lactams in allergic individuals or when new cephalosporins are brought to market. Clinicians should consider the low likelihood of true cephalosporin allergy when clinically indicated. The purpose of this review is to provide an overview of the role of cephalosporins in clinical practice, and to highlight the incidence of, risk factors for, and cross-reactivity of cephalosporins with other antibiotics.

Delayed-type allergy to articaine with cross-reactivity to other local anesthetics from the amide group

2018 ◽  
Vol 6 (1) ◽  
pp. 305-306 ◽  
Author(s):  
Tiziana Maria Angela De Pasquale ◽  
Alessandro Buonomo ◽  
Stefano Pucci
Keyword(s):  
Local Anesthetics ◽  
Cross Reactivity ◽  
Amide Group

Cephalosporin hypersensitivity: descriptive analysis, cross-reactivity and risk factors

2020 ◽  
Author(s):  
Nidhal TOUATI ◽  
Barbara CARDOSO ◽  
Marie DELPUECH ◽  
Raphaelle BAZIRE ◽  
Nathalie EL KARA ◽  
...  
Keyword(s):  
Risk Factors ◽  
Descriptive Analysis ◽  
Cross Reactivity

scholarly journals Ultrasound-guided deep nerve block may increase the rate of local anesthetics toxicity in HBV carriers: A Randomized clinical trial

2019 ◽  
Author(s):  
Xu-hao Zhang ◽  
Yu-jie Li ◽  
Wenquan He ◽  
Chunyong Yang ◽  
Jianteng Gu ◽  
...  
Keyword(s):  
Risk Factors ◽  
Clinical Trial ◽  
Nerve Block ◽  
Nerve Stimulation ◽  
Local Anesthetics ◽  
Ultrasound Guidance ◽  
Female Gender ◽  
Hbv Infection ◽  
Nerve Stimulator ◽  
Nerve Blocks

Abstract Background: Ultrasound-guidance might decrease the incidence of local anesthetics systemic toxicity(LAST) for many peripheral nerve blocks compared to nerve stimulation. However, it remained uncertain whether ultrasound-guidance would be superior to the nerve stimulation for deep nerve block in the lower extremity. This study was designed to investigate that deep nerve block with ultrasound-guidance would result in a lower rate of LAST comparing to that with nerve stimulator-guidance. Methods: Three hundred patients who were for elective lower limb surgery and desiring lumbar plexus blocks(LPBs) and sciatic nerve blocks(SNBs) were enrolled in this study. Patients were randomly assigned to receive LPB and SNB with ultrasound-guidance (Group U), nerve stimulator-guidance (Group N) and dual-guidance (Group M). The primary outcome was the incidence of the LAST. The secondary outcomes were number of needle redirections, motor and sensory block onset and restoration times in the nerve distributions, and associated risk factors. Results: There were 18 patients with the LAST, including 12 in group U, 4 in group N and 2 in group M. For multiple comparisons among the tree groups, we found that the incidence of LAST in group U(12%) was significantly higher than that in group N(4%)(P=0.037) and group M(2%)(P=0.006). The OR of LAST with HBV infection and female gender was 3.352(95% CI,1.233-9.108, P=0.013 ) and 9.488(95% CI,2.142-42.093, P=0.0004), respectively. Conclusions: For patients undergoing LPBs and SNBs, use of ultrasound may increase the incidence of the LAST. HBV infection and female gender were risk factors for deep nerve block. Trial registration: This study was approved by the human research review committee at the southwest hospital of third military medical university. The protocol was registered prospectively with Chinese Clinical Trial Registry (ChiCTR-IOR-16008099) on March 15th，2016. Keywords: Ultrasound; nerve stimulation; nerve block; female; HBV; LAST

Latex allergy: prevalence, risk factors, and cross-reactivity

Methods ◽  
2002 ◽  
Vol 27 (1) ◽  
pp. 10-14 ◽  
Author(s):  
Kristiina Turjanmaa ◽  
Soili Mäkinen-Kiljunen
Keyword(s):  
Risk Factors ◽  
Cross Reactivity ◽  
Latex Allergy ◽  
Allergy Prevalence

scholarly journals Sulfonamide Allergies

Pharmacy ◽  
2019 ◽  
Vol 7 (3) ◽  
pp. 132 ◽  
Author(s):  
Amber Giles ◽  
Jaime Foushee ◽  
Evan Lantz ◽  
Giuseppe Gumina
Keyword(s):  
Risk Factors ◽  
Drug Allergy ◽  
Antimicrobial Agents ◽  
Treatment Options ◽  
Cross Reactivity ◽  
Definitive Treatment ◽  
Factors Associated ◽  
Immunodeficiency Virus ◽  
The Common ◽  
Immunocompetent Patients

As one of the earliest developed antimicrobial classes, sulfonamides remain important therapeutic options for the empiric and definitive treatment of various infectious diseases. In the general population, approximately 3–8% of patients are reported to experience a sulfonamide allergy. Sulfonamide allergies can result in various physical manifestations; however, rash is reported as the most frequently observed. In patients with human immunodeficiency virus (HIV), dermatologic reactions to sulfonamide antimicrobial agents occur 10 to 20 times more frequently compared to immunocompetent patients. This article describes the incidence, manifestations, and risk factors associated with sulfonamide allergies. The potential for cross-reactivity of allergies to sulfonamide antimicrobials with nonantimicrobial sulfonamide medications is also reviewed. Data suggest that substitutions at the N1 and N4 positions are the primary determinants of drug allergy instead of the common sulfonamide moiety. For patients with an indication for a sulfonamide antimicrobial with a listed allergy, it is important for healthcare practitioners to adequately assess the allergic reaction to determine appropriate management. Rechallenge and desensitization strategies may be appropriate for patients with delayed maculopapular eruptions, while alternative treatment options may be prudent for more severe reactions. Available data suggests a low risk of cross-allergenicity between sulfonamide antimicrobial and nonantimicrobial agents.

Sign in / Sign up

Export Citation Format

Share Document